Dasatinib
Angioimmunoblastic T-Cell Lymphoma
Zhengzhou UniversitySmall moleculePhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 81/ 100
Competitive context
54 Active assets in the Angioimmunoblastic T-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ifosfamide Shandong Provincial Hospital | Phase 4 | BBB |
DEXAMETHASONE Ou Bai, MD/PHD | Phase 2 | BB |
Inno-206 City of Hope Medical Center | Phase 4 | BB |
PREDNISONE TABLETS Shanghai Jiao Tong University School of Medicine | Phase 4 | BB |
Azacitidine National Cancer Institute (NCI) | Phase 4 | BB |
View all 50 →
Same molecule, other indications
Dasatinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
67 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →